The endothelial angiopoietin-Tie signaling pathway in development and disease by Korhonen, Emilia
50/2020













































dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis
WIHURI RESEARCH INSTITUTE
TRANSLATIONAL CANCER MEDICINE PROGRAM
RESEARCH PROGRAMS UNIT
FACULTY OF MEDICINE
DOCTORAL PROGRAMME IN BIOMEDICINE
UNIVERSITY OF HELSINKI
THE ENDOTHELIAL ANGIOPOIETIN-TIE SIGNALING PATHWAY 






TABLE OF CONTENTS 
LIST OF ORIGINAL PUBLICATIONS .......................................................................................................... 5 
ABBREVIATIONS ............................................................................................................................................. 6 
ABSTRACT ......................................................................................................................................................... 7 
REVIEW OF THE LITERATURE ................................................................................................................... 9 
1. STRUCTURE AND FUNCTION OF THE VASCULAR SYSTEM ........................................................... 9 
1.1 The blood vascular system ...................................................................................................................... 9 
1.1.1 Blood vessel structure and function ................................................................................................ 9 
1.2 The lymphatic vascular system ............................................................................................................. 10 
1.2.1 Lymphatic vessel structure and function ...................................................................................... 11 
2. BLOOD AND LYMPHATIC VESSEL DEVELOPMENT AND GROWTH ........................................... 11 
2.1 Embryonic development ....................................................................................................................... 11 
2.1.1 Vasculogenesis and angiogenesis ................................................................................................. 11 
2.1.2 Lymphangiogenesis and lymphvasculogenesis ............................................................................ 12 
2.2 Postnatal development .......................................................................................................................... 13 
2.2.1 Retinal angiogenesis ..................................................................................................................... 13 
2.2.2 Postnatal lymphatic vessel development ...................................................................................... 14 
2.2.3 Angiogenesis and lymphangiogenesis in the adult ....................................................................... 15 
3. MOLECULAR REGULATORS OF THE VASCULAR SYSTEM ........................................................... 15 
3.1 VEGF-VEGFR signaling pathway ........................................................................................................ 15 
3.2 Notch signaling pathway ....................................................................................................................... 16 
3.3 Ang-Tie signaling pathway ................................................................................................................... 16 
3.3.1 Structure and expression of the Ang and Tie molecules .............................................................. 16 
3.3.2 Physiological roles of the Ang-Tie system ................................................................................... 18 
3.3.3 Signaling via the Ang-Tie system ................................................................................................. 20 
4. BLOOD AND LYMPHATIC VESSELS IN DISEASE ............................................................................. 23 
4.1 Blood vasculature in disease ................................................................................................................. 23 
4.1.1 Tumor angiogenesis ...................................................................................................................... 23 
4.1.2 Ocular diseases ............................................................................................................................. 24 
4.1.3 Inflammation ................................................................................................................................. 25 
4.2 Lymphatic dysfunction ......................................................................................................................... 26 
4.3 Ang-Tie system in disease .................................................................................................................... 27 
4.3.1 Ang-Tie system in tumor angiogenesis and metastasis ................................................................ 27 
4.3.2 Ang-Tie pathway in ocular neovascularization ............................................................................ 28 
4.3.3 Ang-Tie pathway in inflammation ................................................................................................ 28 
4.3.4 Mutations affecting the Ang-Tie pathway .................................................................................... 30 
AIMS OF THE STUDY .................................................................................................................................... 31 
MATERIALS AND METHODS ..................................................................................................................... 32 
1. MATERIALS .............................................................................................................................................. 32 
2. METHODS ................................................................................................................................................. 33 
RESULTS AND DISCUSSION ....................................................................................................................... 39 
Loss of endothelial Tie1 receptor impairs lymphatic vessel development (I) ............................................... 39 
Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy (II) .............................. 41 
Tie1 controls angiopoietin function in vascular remodeling and inflammation (III) .................................... 46 
Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment 
into the CNS (IV) ........................................................................................................................................... 51 
CONCLUSIONS AND FUTURE PROSPECTS ............................................................................................ 55 
ACKNOWLEDGEMENTS .............................................................................................................................. 57 





AAV Adenovirus-associated virus 
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Tie Tyrosine kinase with Ig-like and EGF-like domains 
TJ Tight junction 
TNF-α Tumor necrosis factor alpha 
VCAM1 Vascular cell adhesion molecule 1 
VE-cadherin Vascular endothelial cadherin (Cadherin-5, Cdh5) 
VE-PTP Vascular endothelial protein tyrosine phosphatase 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 




Combinatorial targeting of Tie1 and Ang2 also reduced angiogenesis in the retina, suggesting that 
targeting Tie1 in combination with Ang2 can improve anti-angiogenic therapy. 
 
We next analyzed the role of Tie1 in angiopoietin signaling and function in inflammation. We 
found that angiopoietin stimulation promoted Tie1-Tie2 interaction and Tie1 was required for 
normal Tie2 trafficking. Tie1 deletion in mice reduced Ang1- and Ang2-induced vascular 
remodeling. Furthermore, Tie1-deficiency reduced Ang1-induced activation of Tie2 and 
downstream signaling and inhibited the Tie2 agonistic activity of Ang2. In lipopolysaccharide 
(LPS)-induced inflammation, the extracellular domain of Tie1 was rapidly cleaved and this was 
associated with reduced Tie2 activation and loss of Ang2 agonistic activity. Our results thus 
indicated that Tie1 is an important regulator of Ang-Tie2 signaling and agonistic function of Ang2 
is decreased in inflammation. 
 
Finally, we investigated the function of Ang2 in neuroinflammation. We found that Ang2 was 
induced in experimental autoimmune encephalomyelitis (EAE), a rodent model of multiple 
sclerosis (MS). Ang2 overexpression exacerbated the severity of EAE whereas its blockade 
ameliorated EAE. Similarly, treatment of the mice with ABTAA (Ang2-binding and Tie2-
activating antibody), increased Tie2 phosphorylation and this reduced EAE severity, indicating 
that Tie2 activation is beneficial in this model. Our study showed that in neuroinflammation, Ang2 
regulates the expression of EC adhesion molecules, blood brain barrier (BBB) integrity and 
recruitment of leukocytes into the central nervous system (CNS), as well as the pro-inflammatory 
polarization of CNS myeloid cells. These data implicate a role for Ang2 in autoimmune 
neuroinflammation. 
 
Overall, this thesis provides insight into the function of Tie1 and Ang2. Our studies reveal 
previously unknown roles of Tie1 in lymphatic vessel development, postnatal sprouting 
angiogenesis as well as in pathological tumor angiogenesis. We found that Tie1 is a critical 
component of the angiopoietin-Tie2 signaling and in inflammation its cleavage is associated with 
reduced agonistic function of Ang2. Furthermore, our work provides novel possibilities for 
therapeutic targeting of Ang2 in neuroinflammation. A deeper understanding of the functions of 
Tie1 and Ang2 in disease pathogenesis should aid in the development of therapies targeting the 
Ang-Tie signaling system. 
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1.1.1.1 Regulation of vascular permeability 
ECs control the passage of solutes and blood proteins into the tissues. They have different 
morphologies and functions in different type of vessels and organs. Exchange of gases and other 
substances occurs in the capillaries, which are divided into three major types: continuous, 
fenestrated, and sinusoidal. Continuous capillaries have complete endothelial lining and do not 
have openings in their walls. They are found in almost all vascularized tissues such as heart, lung, 
skeletal muscle, and brain.  Fenestrated capillaries have small pores in their EC lining with a 
permeable diaphragm, which allows the transfer of macromolecules. Fenestrated capillaries are 
found in the small intestine, kidneys, and many endocrine organs. Sinusoidal endothelium has 
large fenestrations and a discontinuous basement membrane, which allows the passage of large 
solutes such as plasma proteins. Sinusoids are found in the liver, spleen, bone marrow, lymph 
nodes, and several endocrine glands (Aird, 2007; Augustin and Koh, 2017). 
 
EC permeability is mediated by two pathways. In the paracellular pathway, the solutes and cells 
pass between the ECs, while in the transcellular pathway, they pass through the ECs. Transcellular 
permeability requires specialized membrane structures, such as vesicular vacuolar organelles 
(Dvorak and Feng, 2001). The paracellular route relies on the coordinated opening and closure of 
endothelial cell-cell junctions. EC junctions control vascular homeostasis by regulating the 
permeability to plasma solutes and leukocyte extravasation (Vestweber et al., 2009). Within EC 
junctions, ECs adhere to one another by adhesive transmembrane junctional proteins. Those form 
junctional structures that are linked to the intracellular actin cytoskeleton through intracellular 
partners, which stabilize the junctions.  
 
ECs have two major type of junctions: adherens junctions (AJs) and tight junctions (TJs). The 
organization of the junctions depends on the functional needs of the perfused organ. AJs initiate 
cell-to-cell contacts and regulate EC growth and paracellular permeability. TJs provide a "barrier" 
by regulating permeability and maintaining cell polarity. TJs are highly abundant in the brain 
endothelium, where permeability needs to be tightly controlled. In turn, TJs in the postcapillary 
venules are poorly organized since dynamic trafficking of cells and proteins is required. Major 
components of the AJs are members of the cadherin family, whilst TJs are formed by members of 
the claudins as well as occludin and JAMs. VE-cadherin is the most prominent AJ protein, and it 
plays essential roles in regulating vascular permeability (Dejana, 2004; Dejana et al., 2009). 
 
1.2 The lymphatic vascular system 
 
Unlike the blood vascular system, the lymphatic system is a unidirectional network. It consists of 
blind-ended capillaries that drain fluid into pre-collectors and collecting vessels present in most 
organs. Some organs, including bone, adipose tissue, muscle, endocrine organs, as well as the 
parenchyma of the brain, liver, and kidney, lack or have a very sparse lymphatic network (Petrova 
and Koh, 2018). Recent research shows the presence of lymphatic vessels also in the eye and 
central nervous system, which were previously considered to lack lymphatic vasculature 
(Aspelund et al., 2014, 2015; Louveau et al., 2015; Park et al., 2014). The lymphatic vasculature 
maintains tissue fluid homeostasis by returning the fluid and solutes extravasated from the blood 
capillaries to the cardiovascular system. Lymph flows through lymph nodes into the thoracic duct, 
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